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Abstract
Background: Trans fatty acids are produced either by industrial hydrogenation or by biohydrogenation in the rumens of
cows and sheep. Industrial trans fatty acids lower HDL cholesterol, raise LDL cholesterol, and increase the risk of coronary
heart disease. The effects of conjugated linoleic acid and trans fatty acids from ruminant animals are less clear. We reviewed
the literature, estimated the effects trans fatty acids from ruminant sources and of conjugated trans linoleic acid (CLA) on
blood lipoproteins, and compared these with industrial trans fatty acids.
Methodology/Principal Findings: We searched Medline and scanned reference lists for intervention trials that reported
effects of industrial trans fatty acids, ruminant trans fatty acids or conjugated linoleic acid on LDL and HDL cholesterol in
humans. The 39 studies that met our criteria provided results of 29 treatments with industrial trans fatty acids, 6 with
ruminant trans fatty acids and 17 with CLA. Control treatments differed between studies; to enable comparison between
studies we recalculated for each study what the effect of trans fatty acids on lipoprotein would be if they isocalorically
replaced cis mono unsaturated fatty acids. In linear regression analysis the plasma LDL to HDL cholesterol ratio increased by
0.055 (95%CI 0.044–0.066) for each % of dietary energy from industrial trans fatty acids replacing cis monounsaturated fatty
acids The increase in the LDL to HDL ratio for each % of energy was 0.038 (95%CI 0.012–0.065) for ruminant trans fatty acids,
and 0.043 (95% CI 0.012–0.074) for conjugated linoleic acid (p = 0.99 for difference between CLA and industrial trans fatty
acids; p = 0.37 for ruminant versus industrial trans fatty acids).
Conclusions/Significance: Published data suggest that all fatty acids with a double bond in the trans configuration raise the
ratio of plasma LDL to HDL cholesterol.
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Introduction
Trans fatty acids arise either from industrial hydrogenation, or
from biohydrogenation in ruminant animals. Artificial trans fatty
acids are produced by partial hydrogenation of vegetable or fish
oils with hydrogen gas and a metal catalyst. Consumption of such
industrial trans fatty acids raises the total to HDL cholesterol ratio
in blood and the risk of coronary heart disease [1–5]. Natural trans
fatty acids are produced in the rumens of cows and sheep. They
arise through partial hydrogenation and/or isomerization of cis-
unsaturated fatty acids from the feed by hydrogen produced
during oxidation of substrates, with bacterial enzymes as catalysts.
As a result the fat in milk, butter, cheese and beef contains 2–9%
trans fatty acids [6–8]. Because of the steep reduction in the
production and intake of industrial trans fatty acids, ruminant fats
are now the major source of trans fatty acids in most European
countries [9] and will likely become so in the USA [10].
The effects of ruminant trans fatty acids on lipoproteins and
heart disease are unclear. Some epidemiological studies showed no
association [1,3,11] between ruminant trans fatty acid intake and
heart disease risk, one showed a non-significant inverse association
[2] and one a non-significant positive association [4]. Data on the
effects of ruminant trans fatty acids on plasma lipoproteins in
humans are limited. One study found adverse effects of high
intakes, but not of low intakes of ruminant trans fatty acids [12].
Another study suggested that ruminant trans fatty acids produce
higher LDL and HDL cholesterol levels than industrial trans fatty
acids in women, but not in men [13].
Industrial and ruminant fats contain similar species of trans fatty
acids, but in different proportions (figure 1). Industrial trans fatty
acids come in two kinds: partially hardened vegetable oils mainly
contain trans isomers of oleic acid (figure 1a), the major one being
C18:1 trans-9 or elaidic acid (figure 1d) and C18: 1 trans-10.
Partially hydrogenated fish oils mainly contain trans isomers of
C20:1, 20:2, 22:1 and 22:2 (figure 1f). Partially hydrogenated
vegetable oils also contain smaller amounts of C18: 1 trans-8, and
C18:1 trans-11 or vaccenic acid (figure 1b), and trans isomers of
alpha-linolenic acid may arise during deep-fat frying. All these
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industrial trans fatty acids raise the LDL to HDL cholesterol ratio
[5,14–16].
In milk and meat C18:1 trans-11 (vaccenic acid) is the predominant
trans fatty acid. In addition, ruminant fats contain small amounts of
cis-9, trans-11 18:2 (conjugated linoleic acid, abbreviated to CLA in
this paper unless otherwise mentioned; figure 1c). Cis-9, trans-11 18:2
CLA is also formed from ingested vaccenic acid in animals and in
humans [17]. CLA is also widely sold as a supplement in the form of
capsules. Most CLA capsules contain a mix of cis-9, trans-11 CLA and
another CLA isomer trans-10, cis-12 CLA. These CLA-preparations
are promoted for weight loss, although studies in humans have been
inconclusive on this aspect [18,19].
Countries such as Denmark that have banned the use of trans
fatty acid in foods have excluded ruminant trans fatty acids. The
Figure 1. Structures of cis- and trans fatty acids. Elaidic acid (9-trans-C18:1) is a typical industrial trans fatty acid, produced by partial
hydrogenation of vegetable oil. Vaccenic acid (11-trans-C18:1) is the predominant trans fatty acid in milk and meat from ruminant animals, although
small amounts are also found in industrially hydrogenated fats. The 9,11 isomer of conjugated linoleic acid or CLA (9-cis, 11-trans-C18:2) is found
almost exclusively in ruminant fat; industrial production of CLA yields a mixture of 9,11 and 10,12 isomers. Oleic acid (9-cis -C18:1) is the predominant
cis-unsaturated fatty acid in the diet. The location of the trans bond in trans isomers of alpha-linolenic acid is not known precisely; for this figure it has
been assigned arbitrarily to the 6 location. The same holds for the trans bonds in the trans isomers of C20:1, C20:2, C22:1 and C22:2 that arise from
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) during partial hydrogenation of fish oil.
doi:10.1371/journal.pone.0009434.g001
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US Food and Drug Administration includes ruminant trans fats in
its labeling rules for trans fatty acids, but exempts CLA.
As the effects of the natural trans fatty acids are unclear we here
review effects of different trans fatty acids on lipoprotein levels in
human intervention trials.
Methods
We review randomized intervention trials that investigated effects
of either industrial trans fatty acids, or conjugated linoleic acid, or
other ruminant trans fatty acids on the LDL to HDL cholesterol
ratio, and on LDL and HDL cholesterol concentrations.
Selection of Studies
We searched Medline for all relevant original-research papers
published in English between January 1990 and January 2010
using as search terms: ‘‘(trans fat OR trans fatty acids, OR CLA)
AND LDL’’. We limited our search to human studies. We also
scanned reference lists to ensure completeness.
We selected dietary trials that reported effects of industrial trans
fatty acids, CLA or other ruminant trans fatty acids on LDL and
HDL cholesterol levels. We also included studies that reported
effects of CLA supplements. Such supplements usually contain a
mix of cis-9, trans-11 CLA, the same conjugated linoleic acid as in
ruminant fats, and trans-10, cis-12 CLA.
Studies had to have a parallel, crossover, or Latin-square design.
We excluded before-and-after (sequential) designs that lacked a
control or comparison group or period. Treatment periods had to
be at least 13 days as that is the minimum period to achieve a new
steady-state concentration of plasma lipoproteins [20,21]. Trials in
which subjects lost or gained significant amounts of weight were
excluded [22,23] as this has an effect on blood lipoproteins
independent of dietary composition [24,25].
Statistical Analysis
Some studies compared trans fatty acids with saturated fatty
acids, or compared two sources of trans fatty acids only. We
recalculated these results to effects relative to isocaloric amounts of
cis mono-unsaturated fatty acids according to the equations of
Mensink et al. [26]. To maintain uniformity, we recalculated the
ratio of LDL to HDL cholesterol from mean LDL and HDL levels
for all studies, even where ratios had been reported. Data from
different studies were combined using linear regression analysis
with intake of trans fatty acids as independent and change in the
plasma LDL to HDL cholesterol ratio, LDL cholesterol and HDL
cholesterol as dependent variables. We did not weigh studies by
number of subjects or standard error of the estimate because the
LDL to HDL ratios are calculated on the basis of mean values of
treatment differences within studies without an estimate of
variation. Regression lines were forced through the origin because
a zero change in diet should produce a zero change in blood lipids.
We also tested logarithmic models in order to check whether our
assumption of a linear dose-response relation was appropriate.
All studies of CLA except one [27] used CLA supplements on
top of uncontrolled ad-lib diets. Doses of CLA in these studies
were reported as grams per day. In order to recalculate these to
percent of energy we assumed an energy intake of 2250 kcal/day,
because a usual energy intake is 2500 kcal per day for men and
2000 kcal per day for women, and most studies enrolled
approximately equal numbers of men and women.
Results
Figure 2 shows a flow diagram of the selection of studies for this
review. Table 1 provides an overview of the studies and their
outcomes for the LDL to HDL cholesterol ratio. For industrial
trans fatty acids we started out with the data of Ascherio et al. [28]
and extended these with results of studies on industrial or
ruminant trans fatty acids published since [10,12–15,27,29–41].
There were 23 studies with controlled diets in which the fat in the
diet was provided by the investigators, so-called dietary controlled
studies on industrial trans fatty acids [12–15,27,30–37,40–49], 5
dietary controlled studies on ruminant trans fatty acids
[12,13,29,38,39], and 1 CLA study with dietary control [27]
and 12 studies on CLA supplements in which the diet was not
controlled [50–61]. We excluded two studies in which the subjects
lost significant amounts of weight [22,23] as this is known to
influence lipoprotein levels. We also excluded one study which
used a sequential design [62] and one small Malaysian study which
showed a discordant, extremely strong adverse effect, of industrial
trans fatty acids [63].
The 23 trials provided 28 data points on the effect of industrial
trans fatty acids. Linear regression showed that the plasma LDL to
HDL ratio increased by 0.055 (95% CI 0.044–0.066) for every %
of dietary energy provided by these artificial trans fatty acids in the
place of cis-monounsaturated fat (figure 3a). LDL increased by
0.048 mmol/L (95% CI 0.037 to 0.058; figure 4) and HDL
decreased by 20.01 mmol/L (95% CI 20.013 to 20.007)
(figure 5) for each % of energy from industrial trans fatty acids
replacing cis-monounsaturates.
The 5 trials provided 6 data points on the effect of ruminant
trans fatty acids from milk. Linear regression showed that the
plasma LDL to HDL ratio increased by 0.038 (95% CI 0.012–
0.065) when one % of dietary energy as cis-monounsaturated fat is
replaced by these natural trans fatty acids (figure 3b). LDL
increased by 0.045 mmol/L (95% CI 20.02 to 0.093; figure 4)
Figure 2. Flow chart of a search details for trials included in figure 3. TFA: trans fatty acids.
doi:10.1371/journal.pone.0009434.g002
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and HDL decreased by 20.009 mmol/L (20.025 to 0.007)
(figure 5) for each % of energy from animal trans fatty acids
replacing cis-monounsaturates.
The 13 trials provided 17 data points on the effect of CLA
supplements. Linear regression showed that the plasma LDL to
HDL ratio increased by 0.043 (0.012–0.074) for every % of dietary
energy as CLA replacing cis-monounsaturated fat (figure 3c). LDL
increased by 0.038 mmol/L (95% CI 0.005 to 0.071; figure 4) and
HDL decreased by -0.008 mmol/L (20.023 to 0.007) (figure 5) for
each % of energy from CLA replacing cis-monounsaturates. We
excluded the study of Tricon et al. [62] because of its sequential
design. If we included this study using the baseline values as
control the slope of the regression line for LDL to HDL changed
from 0.043 to 0.041.
The effect of CLA on the LDL to HDL ratio increased to 0.064
per % of energy if we excluded our own study [27] from the
regression analysis. This was the only controlled dietary study on
CLA, but it used a much higher dose of CLA, namely
Figure 3. Results of randomized studies of the effects of diets high in industrial trans fatty acids (---# ---) or ruminant trans fatty
acids (????m????) or CLA (JJJNJJJ) compared with cis-unsaturated fatty acids on the ratio of LDL- tot HDL-cholesterol. a: Results of all studies
on the ratio of LDL- to HDL-cholesterol. Results of studies using saturated fatty acids as comparison group [14,15,30,31,37,38,41,49,60,61] and of the
Transfact study[13], which compared two sources of trans fatty acids were recalculated to effects relative to isocaloric amounts of cis mono-
unsaturated fatty acids according to Mensink et al. [26]. To maintain uniformity, we calculated the ratio of LDL to HDL cholesterol from mean LDL and
HDL levels, even where ratios had been reported. Numbers indicate reference numbers. Point no. 63 was not included in estimating the regression
line because we considered it an outlier. Regression lines were forced through the origin because a zero change in diet should produce a zero change
in blood lipids. The black solid line indicates the best-fit regression for industrial trans fatty acids (y = 0.055x), the dashed line for ruminant trans fatty
acids (y = 0.038x) and the grey line for CLA (y = 0.045x). The slopes of the regression lines were not significantly different. b: Results of randomized
studies of the effects of diets high in ruminant trans fatty acids compared with cis-unsaturated fatty acids on the ratio of LDL- to HDL-cholesterol.
Results of one study using saturated fatty acids as comparison group [38] and of the Transfact study, which compared two sources of trans fatty acids
[13], were recalculated to effects relative to isocaloric amounts of cis mono-unsaturated fatty acids according to Mensink et al. [26]. To maintain
uniformity, we calculated the ratio of LDL to HDL cholesterol from mean LDL and HDL levels, even where ratios had been reported. Numbers indicate
reference numbers. c: Results of randomized studies of the effects of CLA compared with cis-unsaturated fatty acids on the ratio of LDL- to HDL-
cholesterol. To maintain uniformity, we calculated the ratio of LDL to HDL cholesterol from mean LDL and HDL levels, even where ratios had been
reported. Numbers indicate reference numbers. Results of two studies using placebo supplements with a high saturated fat content [60,61]were
recalculated to effects relative to isocaloric amounts of cis mono-unsaturated fatty acids according to Mensink et al. [26].
doi:10.1371/journal.pone.0009434.g003
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approximately 20 grams/day as opposed to doses between 1.8 and
6.8 grams/day in the CLA supplement studies. Most studies used
supplements with a 50:50 ratio of cis-9, trans-11 and trans-10, cis-12
CLAs. If we excluded the study that investigated these CLA
isomers separately [58] and the two interventions that used CLA
with an 80:20 ratio of the cis-9, trans-11 and trans-10, cis-12 isomers
[27,52], the effect of CLA on the LDL to HDL ratio became
0.056.
Figure 4. Results of randomized studies of the effects of diets high in industrial trans fatty acids (---# ---) or ruminant trans fatty
acids (????m????) or CLA (JJJNJJJ) compared with cis-unsaturated fatty acids on LDL cholesterol.
doi:10.1371/journal.pone.0009434.g004
Figure 5. Results of randomized studies of the effects of diets high in industrial trans fatty acids (---# ---) or ruminant trans fatty
acids (????m????) or CLA (JJJNJJJ) compared with cis-unsaturated fatty acids on HDL cholesterol.
doi:10.1371/journal.pone.0009434.g005
Trans Fat and Blood Lipids
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9434
The slope of the regression line for the LDL to HDL ratio was
steeper for industrial trans fatty acids than for ruminant trans fatty
acids or CLA, but the differences between the regression
coefficients did not reach any limit of statistical significance. The
p-value was p= 0.37 for ruminant versus industrial, p = 0.99 for
CLA versus industrial and p= 0.64 for CLA versus ruminant, or
p = 0.36 if we excluded our own study [27]. For ruminant trans
fatty acids the explained variance (R2) of effects on the LDL to
HDL ratio among the studies included in the regression analysis
was 74%. A logarithmic model showed a better fit for the data,
with an explained variance of 89%. However, this model did not
make biological sense because it predicted that a zero intake of
ruminant trans fatty acids would cause an infinitely large decrease
in the LDL to HDL ratio.
Discussion
This review provides the first quantitative comparison of the
effect of ruminant trans fatty acids and CLA with that of industrial
trans fatty acids on blood lipoproteins in humans. Our analysis
shows that all three classes of trans fatty acids raise the ratio of LDL
to HDL, and therefore, presumably, the risk of coronary heart
disease. The effect of ruminant trans fatty acids and CLA on the
LDL to HDL ratio was less than that of industrial trans fatty acids
although the difference was not significant. Further studies will be
needed to decide whether this difference is real or due to chance.
Strengths and Limitations
Our search strategy ensured that we included all important
studies. We cannot completely exclude the possibility of publica-
tion bias. In theory, interests of the sponsoring industry could have
prevented publication of studies that showed an unfavorable
increase in LDL and/or a decrease in HDL-cholesterol. We have
no indications that results have not been published, but if they
exist then the adverse effects of ruminant trans fatty acids and CLA
on blood lipids may have been larger than shown here.
All supplement trials included were performed double-blind,
except for one which was single blind [51]. In the dietary
studies masking was attempted but was probably incomplete.
However, we consider it unlikely that this influenced cholesterol
concentrations.
In our calculations we did not take differences in size between
the studies into account. This would require standard errors of
treatment differences within studies, which generally were not
given. We do not think this will affect our estimations much,
because individual studies are close to the estimated regression line
(figure 3). For the CLA studies this is also not expected to affect the
line considerably, because almost all studies had between 50 and
100 participants. Thus, weighing for size is not expected to change
the regression line much.
Comparison of the effect of the two CLA isomers – the 9,11
isomers found in milk and supplements, and the 10,12 isomer
found only in supplements - is difficult as most studies only
investigated a 50:50 mixture of cis-9, trans-11 and trans-10, cis-12
CLA. The studies that investigated either the 80:20 mixture or
pure cis-9, trans-11 CLA found less of an effect. We cannot exclude
that trans-10, cis-12 CLA raises the LDL to HDL ratio more than
cis-9, trans-11 CLA. However, it is clear that all CLA compounds
raise the LDL to HDL ratio.
Validity of the Models
The first study on industrial trans fatty acids and blood
lipoproteins in humans [47] reported an adverse effect of trans
fatty acids, but a high dose not found in regular diets. At the time it
was suggested that there was a threshold for this effect and that
lower intakes of trans fatty acids as found in regular foods had no
effect. Later studies showed that this was not the case and that the
effect was proportional with the dosage up to very high intakes
(figure 3). Mensink et al. [26] showed that effects of saturated and
cis- and trans- unsaturated fatty acids on lipoproteins are also
linear with dosage. Figures 3b and c suggest that the same holds
true for conjugated linoleic acid and ruminant trans fatty acids, and
that there is no threshold level below which these trans fatty acids
fail to raise the LDL to HDL ratio.
Figure 3b depicts the dietary studies on ruminant trans fatty
acids. In this figure only studies on total ruminant trans fatty acids
are included because there are no dietary studies on isolated
vaccenic acid or pure cis-9, trans-11 CLA. For total ruminant trans
fatty acids the explained variance (R2) was 74%. A logarithmic
model showed a better fit with an R2 of 89%. However,
calculations of explained variance are of limited value because
intakes of ruminant trans fatty acids did not follow a normal
distribution (figure 3b). Besides, this model does not make
biological sense because a zero intake would cause an infinitely
large decrease in the ratio of LDL to HDL. Furthermore, the
logarithmic model was completely driven by a single study that
found a decrease in the ratio of LDL to HDL with a small increase
in the intake of ruminant trans fat. That study was underpowered
to convincingly show an effect of this low dose [12]. Therefore, we
consider the linear regression line the most parsimonious model
for these studies. However, it is based on a limited number of data
points and the coefficient may change as more data become
available.
For the CLA studies the linear model also seems the most
appropriate model. Figure 3c again gives no indication for a
threshold below which CLA has no effect.
It was earlier shown that various trans 18:1 isomers (fig 1a;
[47,48]), trans isomers of alpha-linolenic acid (fig 1e; [16]) and trans
C20 and C22 isomers (fig 1f; [14,15]) raise the LDL to HDL
cholesterol ratio. Our present review adds ruminant trans fatty
acids and CLA. This suggests that all trans fatty acids, including cis-
9, trans-11 CLA, share the same qualitative effect on the LDL to
HDL cholesterol ratio in humans (Figure 3a). Although the slopes
of the regression lines in figure 3a were not significantly different,
we cannot exclude the possibility that small differences in effect
exist between trans fatty acids from various sources.
A stringent of our conclusion will be provided by an ongoing
study at the United States Department of Agriculture [http://
clinicaltrials.gov/ct2/show/NCT00942656]. It examines pure
vaccenic acid, a trans fatty acid not included in our analyses. We
predict that 3% of energy from vaccenic acid will significantly raise
the LDL to HDL cholesterol ratio by about 0.11 compared to cis-
monounsaturates. The study also examines 1% of energy from cis-
9, trans-11 conjugated linoleic acid. This should raise the LDL to
HDL ratio, but not sufficiently to reach significance. A Swiss study
[http://clinicaltrials.gov/ct2/show/NCT00933322] will examine
the effect of 2% of energy from trans fatty acids in butter. This
should raise the LDL to HDL cholesterol ratio by 0.076, but the
study may lack the statistical power to pick up this effect.
Public Health Implications
Most of the trans fatty acids in milk and meat consist of vaccenic
acid and other trans-mono-unsaturated fatty acids similar to those
found in partially hydrogenated vegetable oils (figure 1). Our
results suggest that all such fatty acids with a double bond in the
trans configuration raise LDL and lower HDL cholesterol.
Removing all such ruminant trans fatty acids from the diet would
lower the total trans fatty acid intake in the United States and
Trans Fat and Blood Lipids
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Europe by about 0.5% of energy [9,64] and might therefore
reduce cardiovascular disease risk by 1.5 to 6% [5]. Such a specific
removal of ruminant trans fatty acids from milk and meat is,
however, technically not feasible. Our results do reinforce the
widespread advice to reduce intake of ruminant fats, because these
are also the major source of saturated fatty acids in affluent diets.
Recent changes in dairy cattle feeding have led to milk with a
lower content of saturated fatty acids and a higher content of cis-9,
trans-11 CLA and other dairy trans fats [65]. Our data suggest that
the effect of these changes on heart disease risk in consumers of
milk and meat fat are at the very least equivocal.
CLA is a minor animal trans fatty acid. The effect of dietary
CLA on cholesterol will be negligible if we assume that our model
is correct. However, intakes from supplements can easily reach 3
grams of CLA a day. This should increase the LDL to HDL
cholesterol ratio by 0.050, which would correspond with a 3 to
12% increase in the risk of cardiovascular disease [5].
Conclusion
Based on this overview we speculate that all fatty acids with one
or more bonds in the trans configuration raise the ratio of LDL to
HDL cholesterol irrespective of their origin or structure. Thus, our
results provide an additional argument besides the high content of
saturated fatty acids to lower the intake of ruminant animal fats.
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